Skip to main content
Publications
Arana A . Estudios descriptivos e híbridos . Presented at the VI Encuentro Nacional de Farmacovigilancia y XVI Encuentro Internacional de Farmacovigilancia de las Américas Meeting; October 29, 2019. Bogota, Colombia.
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Gutierrez L , Booth H, Dedman D, Crellin E, Kaye JA, Franzoni C , Arana A , Schmitt-Egenolf M, Sundstrom A, Bystrom C. Case validation of cutaneous lymphoma to minimize protopathic bias . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):645. doi: 10.1002/pds.4864
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuay LJ, Jan Atsma W, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Proportions of cancer cases in primary care, hospital, and cancer registry data among patients treated for overactive bladder. Letter to editor . Epidemiology. 2019 Mar;30(2):e8-9. doi: 10.1097/EDE.0000000000000953
Gomez A, Arana A , Huerta C, Montero D, Martin E, Comas M, Giner M, Macia MA, Gil M, Morros R, Duarte T. Use of data based on computerized clinical history ('real world data') in pharmaco-epidemiological studies . Presented at the Spanish Agency of Medicines and Health Products-AEMPS; November 20, 2018. Madrid, Spain.
Margulis AV , Linder M, Arana A , Pottegard A, Berglind IA, Bui CL , Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S , Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom . PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuy LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Value of free-text comments for validating cancer cases using primary-care data in the United Kingdom . Epidemiology. 2018 Sep;29(5):e41-2.
Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B , Bui C , Arana A , Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S . Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany . Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):953-61. doi: 10.1002/pds.4584
Arana A , Margulis AV , McQuay LJ, Ziemiecki R , Bartsch JL , Rothman KJ , Franks B, D Silva M, Appenteng K, Varas-Lorenzo C, Perez-Gutthann S . Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder: a cohort study in the UK . Pharmacotherapy. 2018 Jun;38(6):628-37. doi: 10.1002/phar.2121.
Margulis AV , Fortuny J , Kaye JA, Calingaert B , Reynolds M , Plana E , McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S , Arana A . Validation of cancer cases using primary care, cancer registry, and hospitalization data in the UK . Epidemiology. 2018 Mar;29(2):308-13. doi: 10.1097/EDE.0000000000000786